AnaSpec this week released its latest series of Protease or Proteinase-Activated Receptors, or PAR, peptides. A total of 17 new PARs were launched.
Monogram Biosciences said this week that beginning July 15 its HERmark Breast Cancer Assay will be available to doctors for assessing HER2 status in patients with breast cancer.
The assay provides a “precise and quantitative” measurement of HER2 total protein and HER2 homodimer levels, according to the company. HERmark will be offered as a CLIA-validated assay through Monogram’s CAP-certified clinical laboratory.